Comunicados de prensa AbbVie Salud y ciencias de la vida — Feed RSS y monitoreo en vivo
PPN World sigue el feed RSS de AbbVie en tiempo real — 5 comunicados indexados en los últimos 30 días, el más reciente llegó hace 4 h. Síguelo con alertas de búsquedas guardadas, resúmenes con IA y búsqueda de texto completo, o conecta la URL RSS de abajo a tu propio lector.
URL del feed RSS de AbbVie
https://news.abbvie.com/index.php?s=2429&pagetemplate=rssSobre este feed
AbbVie forma parte de los más de 1200 feeds de comunicados que PPN World monitorea de forma continua — una fuente en inglés centrada en el sector Salud y ciencias de la vida, clasificada bajo «Estados Unidos» en nuestro índice por país. Cada comunicado se deduplica, se geolocaliza y se enriquece con un resumen de IA, y puedes añadir alertas de búsquedas guardadas sobre cualquier palabra clave que publique. AbbVie es una fuente especializada de bajo volumen — 5 comunicados en los últimos 30 días: el tipo de fuente que merece una alerta más que un desplazamiento.
Cómo seguir los comunicados de AbbVie
- Copia la URL del feed RSS de AbbVie que aparece arriba.
- Pégala en cualquier lector RSS (Feedly, Inoreader, NetNewsWire…) para recibir el feed sin procesar.
- O sigue AbbVie en PPN World para añadir deduplicación, alertas de búsquedas guardadas y resúmenes con IA en los más de 1200 feeds.
Últimos comunicados de AbbVie
- JUVÉDERM® Day Returns to U.S. on August 19hace 4 h
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first...
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areatahace 1 d
RINVOQ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whic…
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligohace 1 d
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas…
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)hace 6 d
COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met...
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientshace 13 d
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹...
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Developmenthace 16 d
SkinMedica® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of...
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphomahace 23 d
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in...
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphomahace 30 d
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in...
- AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areatahace 31 d
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key...
Los comunicados más recientes de esta fuente se transmiten en vivo para los miembros de PPN World.